2022H1GSK performance: the structural adjustment has achieved initial results, the performance of star products has reached a new high, and the full-year forecast has been raised

Earnings season is he.

GSK's total revenue in the first half of the year was 1119 billion pounds, a year-on-year increase of 2

HIV field: Newly launched drugs show impressive growth

GSK has been a pioneer in the fight against HIV in the medical community since the beginning of the AIDS epidemic 40 years a.

Oncology field: After returning to the track, it is expanding its layout

Oncology is a field that GSK has re-entered since 2016 and has increased its deployment in recent yea.

Among them, the anti-PD-1 antibody Jemperli (dostarlimab, dotalimab) developed by the company was granted accelerated approval by the FDA in April 2021 for the treatment of patients with disease progression after receiving platinum-containing chemotherapy and carrying mismatch repair deficiency (dMMR) DNA repair abnormaliti.

Blenrep, an antibody-drug conjugate (ADC) targeting B cell maturation antigen (BCMA), is the world's first approved anti-BCMA therapy, with sales of £55 million in the second quarter of this ye.

Zejula (niraparib, niraparib) is GSK's acquisition of Tesaro for $1 billion in 201 As a PARP inhibitor, it is suitable for regenerative epithelial ovarian cancer, fallopian tube cancer, complete or partial response to platinum chemothera.

Respiratory system immune inflammation field: two major single products contributed to the main performance

The field of respiratory immune inflammation is also a key area for GSK, with a cumulative revenue of 2 billion pounds in the first half of the ye.

Nucala (mepolizumab), a fully human monoclonal antibody that specifically targets interleukin 5 (IL-5), is the first and only drug in the world approved for the treatment of rare diseases with high blood pressure Targeted biological therapy for eosinophilic syndrome (HES), which is also FDA-approved as an add-on maintenance therapy for severe eosinophilic asthma (SEA), eosinophilic granuloma polypitis (EGPA) and rhinosinusitis and nasal polyps (CRSwN.

Benlysta (belimumab) is the first B lymphocyte stimulating factor developed by GSK, and the first treatment drug for systemic lupus erythematosus (SLE) marketed globally in 50 yea.

New crown business: neutralizing antibodies or lack of stamina

While the new crown epidemic has brought a crisis to the pharmaceutical industry, it has also brought many opportuniti.

Shingles vaccine sales more than double as demand recovers

       Although GSK has not been able to enjoy the dividends of the new crown vaccine, the market performance of its shingles vaccine Shingrix has been stro.

       In the field of general medicines, GSK's blockbuster COPD triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhalation powder) reached 807 million pounds with a growth rate of 4

       GSK was established in December 2000 as an R&D-based pharmaceutical and healthcare products compa.

       In order to maintain its global leadership, GSK has taken a series of measures, including expanding pipelines and spinning off business.

       This performance report is the first time GSK has disclosed its performance after the divestiture of the consumer security departme.

       Not only GSK , but in the face of the rapidly changing global market, pharmaceutical giants such as Pfizer and Merck are also completing their own transformation by divesting non-core business.

Pfizer spun off Pfizer Upjohn and merged with Mylan to form a new global pharmaceutical company, Huiz.

Merck spun off Ogallon, and focused on products such as tumors and vaccin.

       Splits, mergers and acquisitio.


may have become normal operations for pharmaceutical companies in transiti.

       Main references:

        https://.

weix.

.

com/s/XtKtYrPRUcJxL7Elp4N1.

        ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infecti.

        The mystery of Jemperli's rectal cancer breakthrou.

        Janssen Announces US FDA Breakthrough Therapy

       Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Canc.

        GSK 2022 first half financial repo.